Affordable Access

Therapeutic potential for cytokine antagonists: Thalidomide and pentoxifylline in Hansen's disease.

Authors
  • Peterson, T C
Type
Published Article
Journal
The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses
Publication Date
Jan 01, 1995
Volume
6
Issue
1
Pages
30–33
Identifiers
PMID: 22514378
Source
Medline
Keywords
License
Unknown

Abstract

Cytokine antagonists are a group of drugs defined by their actions on specific cytokines. Cytokine antagonists can inhibit action of cytokines by acting directly on receptors, by affecting production of cytokines or by binding to cytokines and preventing their subsequent action. Recent evidence suggests that Hansen's disease, which is characterized by reactional states, is associated with elevated serum levels of tumour necrosis factor-α (tnf-α) and interleukin-1β during these reactional states. Thalidomide, a drug used to treat reactional states in Hansen's disease, has been reported to enhance degradation of tnf-α mrna. Pentoxifylline has also been reported to alter tnf-α mrna levels by inhibiting tnf-a transcription. Combination of these two drugs as cytokine antagonists may prove to be beneficial as therapeutic agents in the treatment of reactional states in Hansen's disease. Pentoxifylline may prove to be beneficial in the treatment of reactional states in Hansen's disease patients who are female and of childbearing age. Cytokine antagonists alone or in combination will likely fill a niche in future therapeutics.

Report this publication

Statistics

Seen <100 times